An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCAR-AIO for the Treatment of Relapsed/Refractory Autoimmune Diseases (r/r AID)
Latest Information Update: 13 Mar 2025
At a glance
- Drugs LCAR-AIO (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Myositis; Systemic lupus erythematosus; Systemic scleroderma
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Nanjing Legend Biotech
- 13 Mar 2025 New trial record